Mascarenhas L, Chi YY, Hingorani P, et al. - Among patients with rhabdomyosarcoma (RMS) in first relapse with unfavorable prognosis, bevacizumab was compared with temsirolimus, when administered in combination with cytotoxic chemotherapy, to prioritize bevacizumab or temsirolimus for additional investigation in RMS. In a random manner, the patients were allocated to receive bevacizumab on day 1 or temsirolimus on days 1, 8, and 15 of each 21-day treatment cycle, together with vinorelbine on days 1 and 8, and cyclophosphamide on day 1 for a maximum of 12 cycles. A superior event-free survival was provided by temsirolimus vs bevacizumab and therefore, temsirolimus was chosen for additional research in newly diagnosed patients with intermediate-risk RMS.